Spanish world market leader for nucleic acid-based virus screening in blood banks, Grifols, has confirmed the purchase price for US-based Hologic’s NAT donor screening unit.
https://european-biotechnology.com/wp-content/uploads/2024/04/john-rex.jpg472420h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2016-12-15 07:50:002016-12-15 07:50:00F2G: Medical reference
At the beginning of October, Isabel De Paoli assumed the position of Chief Strategy Officer at German healthcare company Merck GmbH. She will head the Group Strategy and Transformation Function, which has just been created.
https://european-biotechnology.com/wp-content/uploads/2024/04/Orion.png450970Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2016-12-14 09:36:332016-12-14 09:36:33Oncology: Orion teams up with Wi2
Dutch-German molecular diagostics specialist Curetis has bagged debt finanancing from the European Investment Bank (EIB) to expand its automated multiplex PCR platform Univero. The company will receive €10m immediately. Further €15m are milestone-dependent.
In order to prepare for the start of Phase III trials with its lead drug candidate Nefecon, Pharmalink AB has made several new appointments. Among them Kari Sandvold, who will take over as Vice President Pharmaceutical Development and Manufacturing.
While competitor Eli Lilly has abandoned commercialisation of its Alzheimer’s therapy solanezumab due to lack of efficacy in a pivotal Phase III study, Genentech has tabled data supporting further development of its Phase III drug crenezumab. The anti-Abeta antibody is highly homologous to solanezumab.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00redak/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngredak2016-12-12 09:09:012024-03-26 16:02:58Crenezumab data support Amyloid-beta targeting
Copenhagen-based Symphogen is losing its long-time CEO Kirsten Drejer, who co-founded the Danish antibody specialist in 2000. In her place, erstwhile CFO Martin Olin is taking over the helm.
https://european-biotechnology.com/wp-content/uploads/2024/04/martin-olin.jpg473420h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2016-12-12 00:00:002016-12-12 00:00:00Symphogen: Big shoes to fill
French immunotherapy company TxCell has teamed up with Inserm Transfert, the tech transfer subsidiary of the French National Institute of Health and Medical Research Inserm, to develop immuno-suppressive regulatory T cells.
UK researchers have identified a highly conserved target structure that can be directed to rush dividing cancer cells into premature division and cell death.
Grifols confirms €1.75bn acquisition in transplantation safety
Latest NewsSpanish world market leader for nucleic acid-based virus screening in blood banks, Grifols, has confirmed the purchase price for US-based Hologic’s NAT donor screening unit.
F2G: Medical reference
AppointmentsAntifungal drug developer F2G Ltd has appointed distinguished research scientist John Rex to the position of Chief Medical Officer.
Merck: Strategic hike
AppointmentsAt the beginning of October, Isabel De Paoli assumed the position of Chief Strategy Officer at German healthcare company Merck GmbH. She will head the Group Strategy and Transformation Function, which has just been created.
Oncology: Orion teams up with Wi2
Latest NewsFinnish theranostics specialist Orion Corporation is set to fill its oncology pipeline through a drug development alliance.
Curetis bags EIB debt financing and expands
Latest NewsDutch-German molecular diagostics specialist Curetis has bagged debt finanancing from the European Investment Bank (EIB) to expand its automated multiplex PCR platform Univero. The company will receive €10m immediately. Further €15m are milestone-dependent.
Pharmalink: Gaining momentum
AppointmentsIn order to prepare for the start of Phase III trials with its lead drug candidate Nefecon, Pharmalink AB has made several new appointments. Among them Kari Sandvold, who will take over as Vice President Pharmaceutical Development and Manufacturing.
Crenezumab data support Amyloid-beta targeting
Latest NewsWhile competitor Eli Lilly has abandoned commercialisation of its Alzheimer’s therapy solanezumab due to lack of efficacy in a pivotal Phase III study, Genentech has tabled data supporting further development of its Phase III drug crenezumab. The anti-Abeta antibody is highly homologous to solanezumab.
Symphogen: Big shoes to fill
AppointmentsCopenhagen-based Symphogen is losing its long-time CEO Kirsten Drejer, who co-founded the Danish antibody specialist in 2000. In her place, erstwhile CFO Martin Olin is taking over the helm.
TxCell gains Treg rights
Latest NewsFrench immunotherapy company TxCell has teamed up with Inserm Transfert, the tech transfer subsidiary of the French National Institute of Health and Medical Research Inserm, to develop immuno-suppressive regulatory T cells.
Researchers report ubiquitous cancer target
Latest NewsUK researchers have identified a highly conserved target structure that can be directed to rush dividing cancer cells into premature division and cell death.